Pharmacological study of the novel compound FLZ against experimental parkinson’s models and its active mechanism

Author： Feng WeiHong   Wei HuaiLing   Liu Geng  

Publisher： Humana Press, Inc

ISSN： 0893-7648

Source： Molecular Neurobiology, Vol.31, Iss.1-3, 2005-02, pp. : 295-300

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gene therapy for Parkinson’s disease

By Le Hoang N   Frim David M  

Expert Opinion on Biological Therapy, Vol. 2, Iss. 2, 2002-02 ,pp. : 151-161

Informa Healthcare

Access to resources Recommend Favorite

Synthesis and Pharmacological Study of Rho-Kinase Inhibitors: Pharmacomodulations on the Lead Compound Fasudil

By Logé Cédric   Siomboing Xavier   Wallez Valérie   Scalbert Elizabeth   Bennejean Caroline   Cario-Tourmaniantz Christelle   Loirand Gervaise   Gressier Bernard   Pacaud Pierre   Luyckx Michel  

Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 18, Iss. 2, 2003-04 ,pp. : 127-138

Informa Healthcare

Access to resources Recommend Favorite

A theoretical study of spin states in Ni-S4 complexes and models of the [NiFe] hydrogenase active site

By Bruschi Maurizio   Gioia Luca   Zampella Giuseppe   Reiher Markus   Fantucci Piercarlo   Stein Matthias  

JBIC Journal of Biological Inorganic Chemistry, Vol. 9, Iss. 7, 2004-10 ,pp. : 873-884

Springer Publishing Company

Access to resources Recommend Favorite

Proteomic approach to studying parkinson’s disease

By Zhang Jing   Goodlett David  

Molecular Neurobiology, Vol. 29, Iss. 3, 2004-06 ,pp. : 271-288

Humana Press, Inc

Access to resources Recommend Favorite

Environmental toxins and α-synuclein in Parkinson’s disease

By Liu Yanying   Yang Hui  

Molecular Neurobiology, Vol. 31, Iss. 1-3, 2005-02 ,pp. : 273-282

Humana Press, Inc

Access to resources Recommend Favorite